AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal Extravascular Lead (SECURE EV) study (n=18) followed subjects with an AtaCor Medical EV-ICD lead connected to a commercially available ICD pulse generator for up to 3 months. Data from all 36 clinical study patients will be presented as a Late-Breaking Clinical Trial at the Asia Pacific Heart Rhythm Society (APHRS) Scientific Session 2022 in Singapore on November 20, 2022.
AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter defibrillator (EV-ICD) study during the upcoming Stanford Biodesign New Arrhythmia Technologies Retreat. The presentation, leading up to the Heart Rhythm 2022 Scientific Congress in San Francisco, is scheduled for 9:50 a.m. on Thursday, April 28, 2022, in Palo Alto, CA.
ATACOR MEDICAL TAKES HOME 2021 OCTANE HIGH TECH AWARD
Facing two other finalists, AtaCor Medical was recognized as the winner of the “Deal of the Year
” category at OCTANe’s 2021 High Tech Awards ceremony
on Thursday, September 23. The reception was held at the Balboa Bay Resort in Newport Beach, CA.
Rick Sanghera, cofounder and CEO of AtaCor Medical,
accepts the “Deal of the Year” award at OCTANe’s 2021 High Tech Awards ceremony.
ATACOR MEDICAL RECOGNIZED AS FINALIST IN 2021 OCTANE HIGH TECH AWARDS
Following a successful $25M Series B round of financing, AtaCor Medical has been recognized as one of five finalists in the 27th annual OCTANe High Tech Awards in the “Deal of the Year” category. OCTANe, Orange County’s technology and life sciences accelerator organization, will announce the winners Thursday, September 23 at the Balboa Bay Resort in Newport Beach, CA.
ATACOR MEDICAL RELEASES NEW DATA DURING THE HEART RHYTHM SOCIETY 2020 SCIENTIFIC SESSIONS
San Clemente, CA, April 28, 2020 - AtaCor Medical, Inc.
announced today that is has completed a $25M Series B financing. The financing syndicate, led by a corporate partner, includes existing investors Broadview Ventures and aMoon Fund as well as new investors Hatteras Venture Partners, Catalyst Health Ventures (CHV), and Longview Ventures, a Broadview affiliate…
New results support the feasibility of an entirely extracardiac pacing method in a heterogeneous patient population, using a minimally invasive, parasternal delivery approach, with adequate sensing and thresholds suited for temporary pacing…
San Clemente, CA, September 18, 2018 – AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Isreal-based a Moon Ventures, the financing also includes participation from a corporate partner…
STANFORD BIODESIGN NEW ARRHYTHMIA TECHNOLOGIES RETREAT
APRIL 28, 2022 • PALO ALTO, CA
HEART RHYTHM SOCIETY SCIENTIFIC SESSIONS
APRIL 29 – MAY 1, 2022 • SAN FRANCISCO, CA